CN1814148B - Chinese medicine composition for treating prostatitis and use thereof - Google Patents
Chinese medicine composition for treating prostatitis and use thereof Download PDFInfo
- Publication number
- CN1814148B CN1814148B CN 200510061802 CN200510061802A CN1814148B CN 1814148 B CN1814148 B CN 1814148B CN 200510061802 CN200510061802 CN 200510061802 CN 200510061802 A CN200510061802 A CN 200510061802A CN 1814148 B CN1814148 B CN 1814148B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- portions
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a Chinese medicinal combination for curing prostatitis and the application thereof, characterized by using Membranous Milkvetch Root, Rhizoma Anemarrhenae, Amur Corktree Bark, Chinese Thorowax Root, Amber Succinum, Plantain Seed, Mongolian Dandelion Herb and Oriental Waterplantain Rhizome as composition, scientifically composing prescriptions, elaborately processing, and obtaining satisfied effect in clinic application. The preparation method comprises the following steps: weighing each raw material according to the prescription ratio, adding water to seven medicines except the Amber Succinum for decoction twice, the added water just covering the medicines for each time, combining the two decoction liquid, filtering and obtaining a filtrate 2, condensing the filtrate into an extract with a proportion of 1.15-1.35, drying under the temperature of 45-55 DEG C, and obtaining a dry extract; combining the dry extract and the Amber Succinum, grinding into powder, and preparing the active component of the inventive medicine; grinding the active component and sieving with a 100 mesh screen, uniformly mixing with ethanol and starch and so on, moistening, softening and taking out till agglomeration, and preparing granule. The invention has functions of benefiting Qi and helping restore vitality, clearing heat and promoting diuresis, and promoting the blood circulation and dismishing inflammation, and adopts oral form, convenient to use, good in taste, and easy to be accepted by patients, and has characters of good curative effect, short period of treatment, low price, no toxicity and side effect as well bad reaction on liver, kidney and other visceras, and it is an ideal effective medicine for curing prostatitis.
Description
Technical field
The present invention relates to drug world, specifically a kind of is the prostatitic Chinese medicine composition of treatment and the application thereof of main component with Chinese medicine.
Background technology
Prostatosis has become the commonly encountered diseases and the frequently-occurring disease of adult male, and the sickness rate height ranks first, account for clinical near half, and main age of onset is between 18 years old to 50 years old, often per urethram scorching, seminal vesiculitis or attached highland inflammation cause.As male's main attached gonad, prostatosis mainly is by genital system infection, and main trafficability characteristic propagation, at the different development stage prostate different diseases can take place.According to domestic statistics, prostatitis is the highest with between twenty and fifty people's prevalence, and the number of going to a doctor because of prostatitis in policlinic accounts for prescription on individual diagnosis patient's male 25% to 30%.Clinical have acute and chronic, bacterial infection and non-infectious, specificity and non-specific branch.The categories such as " acute pyogenic infection of perineum, nebulousurine, stranguria caused by overstrain, stranguria marked by chyluria, smart turbid " that belongs to the traditional Chinese medical science.It can cause that also the genito-urinary system that continues or show effect repeatedly infects completely without symptom.Prostatitic route of infection is hematogenous infection or direct extension.Wherein the per urethra direct extension is more sees.Main diseases is because of being that antibacterial enters body of prostate through ducts of prostate gland and causes inflammation; Or prostatic hyperplasia and calculus make prostatic urethra distortion, crooked congested, loses prostatitis is taken place for the immunity of non-pathogenic bacteria.Or the urethra apparatus brings antibacterial into when using or goes up the urinary tract inflammation and degerm descendingly, causes prostate and infects; Or hematogenous infection, often being secondary to skin, tonsil, dental caries, the actute infection of intestinal respiratory tract, antibacterial arrives prostatic part by blood and causes infection.Its clinical manifestation has General Symptomies such as heating shiver with cold or systemic pain, weak weakness, anorexia, nausea and vomiting, constipation with dry stool, headache; Or the perineum suprapubic region has the weight sense, and sitting, defecation increase the weight of, and to local symptoms such as waist, lower abdomen, back, thigh root radiation; The sound of rain pattering or see pyuria behind causalgia, urgent micturition, frequent micturition, the urine when urinating, can occur urinating when serious smooth, the urine rheology is thin, even causes urinary tract symptom such as urine retention; Rectum distension, just urgency or defecation pain, the white rectum symptom that waits of urethra stream during stool; Property symptoms such as hyposexuality, sexual anhedonia, sexual impotence, hemospermia.
In one's old age, testicular function is degenerated, and hormonal readiness reduces, and the prostatitis sickness rate descends, and the sickness rate of benign prostate hyperplasia obviously raises.This kind disease is quite high at the sickness rate of American-European countries, and is relatively low at the sickness rate of China, but the existing in recent years trend that increases rapidly.Prostatitis is the modal diseases of urinary system of the right side of fifty male, is listed as the 3rd in the elderly men diseases of urinary system.Acute prostatitis is meant the acute inflammation due to the non-specific bacterial infection of prostate, mainly shows as urgent micturition, frequent micturition, dysurea, rectum and perineal position pain, and fever with aversion to cold etc. is arranged more, belongs to the traditional Chinese medical science " pyretic stranguria " category.The property prostatitis be chronic inflammatory disease due to the non-specific bacterial infection of prostate, mainly show to urinate slowly at frequent micturition, urgent micturition, night and increase companion's dysurea or hypogastric region, perineal position pain discomfort, the course of disease is longer.The traditional Chinese medical science belongs to,, smart turbid " category, be common in male adults.From the clinical onset rate, even most of senile prostatic hyperplasia of prostate patient is also with prostatitis.Primary disease and male sexual disorder (hyposexuality, premature ejaculation, painful ejaculation, seminal emission) substantial connection arranged.
At present, doctor trained in Western medicine is used antibiotic therapy to prostatitis more.Disperse enters prostatic uneven difference according to antimicrobial drug, and antibiotic is classified.High-caliber have trimethoprim, lincomycin, an erythromycin etc.; Medium level chloromycetin, lincomycin arranged; Low-level have doxycycline, kanamycin, nitrofurantoin, oxytetracycline, benzylpenicillin, polymyxin B, rifampicin and most sulphonamidess etc. ampicillin, pioneer I number, pioneer IV number.Medicine penetrates prostate easily during acute inflammation, the patient that part prostatic fluid the inside leukocyte disorder raises, and antibiotic has certain effect.But antibacterials are difficult to infiltrate through prostate during chronic inflammatory disease, and treatment is difficulty comparatively, can not find malignant bacteria in the prostatic fluid, does not have specific short so far.In addition, after antibiotic is stopped using, certain recurrence possibility is arranged.And antimicrobial drug has the influence of certain side effect to patient's hepatic and renal function.
Because primary disease cause of disease complexity, the course of disease is touching, and is obstinate difficult, still do not have ideal effect method at present clinically, how dissatisfied in treatment.The present invention is directed to the deficiency of above-mentioned technology, adopt this chronic disease of treatment by Chinese herbs prostatitis, especially chronic prostatitis, the Chinese medicine primary disease is paid attention to the integral body of compound recipe and recuperated under medical treatment advantage, and is reliable with its curative effect, drug safety is subjected to the attention of Chinese scholars day by day.Thereby make the traditional Chinese medicine of motherland in its treatment, bring into play very big effect, and prospect allow people's optimism.Feature of the present invention is mostly to be damp invasion of lower energizer at chronic prostatitis to tie in smart chamber and bladder, and treatment is held up unit with QI invigorating, and clearing away heat-damp and promoting diuresis, anti inflammatory blood quickening are method.With the Radix Astragali, the Rhizoma Anemarrhenae, Cortex Phellodendri, Radix Bupleuri, succinum, Semen Plantaginis, Herba Taraxaci, Rhizoma Alismatis scientific composition, processing meticulously, clinical use have obtained satisfied effect.Therefore, effective Chinese medicine of development treatment chronic prostatitis has the good application development prospect, will produce remarkable social benefit and economic benefit.
Summary of the invention
Purpose of the present invention is exactly in order to address the above problem, and providing a kind of is that the QI invigorating that has of main component is held up unit with Chinese medicine, clearing away heat-damp and promoting diuresis, and the anti inflammatory blood quickening effect is to treatment prostatitis obvious results Chinese medicine composition and application thereof.
Purpose of the present invention can take following technical scheme to realize:
The prostatitic Chinese medicine composition of a kind of treatment is characterized in that it is that component is formed or made active component and pharmaceutically acceptable additives are formed or make active component and pharmaceutically acceptable additives are formed by the alcohol extract of following main materials by the water extract of following main materials by following main materials:
The Radix Astragali 300～600 weight portion Rhizoma Anemarrhenaes 300～450 weight portion Cortex Phellodendris 300～450 weight portion Radix Bupleuri 300～450 weight portion succinums 300～450 weight portion Semen Plantaginiss 180～300 weight portion Herba Taraxacis 180～300 weight portion Rhizoma Alismatis 120～180 weight portions
Preferable range is:
248～498 parts of 248～498 portions of Cortex Phellodendris of 331～999 parts of Rhizoma Anemarrhenaes of the Radix Astragali
166～498 parts of 166～498 portions of Semen Plantaginiss of 166～498 parts of succinums of Radix Bupleuri
166～498 parts of 166～498 portions of Rhizoma Alismatis of Herba Taraxaci
Its formula optimization is:
The Radix Astragali 450 weight portions, the Rhizoma Anemarrhenae 400 weight portions, Cortex Phellodendri 400 weight portions, Radix Bupleuri 400 weight portions, succinum 400 weight portions, Semen Plantaginis 250 weight portions, Herba Taraxaci 250 weight portions, Rhizoma Alismatis 150 weight portions.
A kind of preparation method for the treatment of prostatitic Chinese medicine composition, wherein: it makes active component by the water extract of following raw materials according and pharmaceutically receptible additives are formed, and the weight portion of each raw material is: 166～498 parts of 166～498 portions of Rhizoma Alismatis of 166～498 parts of Herba Taraxacis of 166～498 portions of Semen Plantaginiss of 166～498 parts of succinums of 248～498 parts of Radix Bupleuri of 248～498 portions of Cortex Phellodendris of 331～999 parts of Rhizoma Anemarrhenaes of the Radix Astragali; Comprise the steps:
(a) take by weighing the Radix Astragali, the Rhizoma Anemarrhenae, Cortex Phellodendri, Radix Bupleuri, succinum, Semen Plantaginis, Herba Taraxaci, the former medicine of Rhizoma Alismatis and that coarser powder is ground in its pulverizing is standby by weight;
(b) Radix Astragali, the Rhizoma Anemarrhenae, Cortex Phellodendri, Radix Bupleuri, Semen Plantaginis, Herba Taraxaci, the Rhizoma Alismatis with described weight portion decocts with water twice, add water serves as easy not have powder at every turn, merge decocting liquid twice, filter to get filtrate, it is 1.15～1.35 extractum that concentrated filtrate becomes proportion, dry under 45～55 ℃, get dry extract;
(c) described succinum merges dry extract, is ground into fine powder, is prepared into the active component of medicine;
(d) with gained active component and the abundant mixing of correctives, make pharmaceutically acceptable any dosage form.During with the medicine extracting in water, add 10 times in water for the first time in the above-mentioned steps (b), decocted 2 hours, add 8 times in water the second time, decocted 1.5 hours; Spissated extractum proportion is 1.20.
Purpose of the present invention can also take following method to realize:
Described pharmaceutically acceptable additives are following one or more: ethylparaben, tartaric acid, citric acid, sodium bicarbonate, lecithin, sodium lauryl sulphate, glycerol, gelatin, Polyethylene Glycol, glycerol monolaurate (Selucire44/14), propylene glycol, dextrin, dried starch.
Its dosage form can be a said dosage form on any pharmaceutics, as effervescent granule electuary, capsule, tablet etc.; Described capsule can be common capsule, effervescent capsule or other various suitable capsules; Described tablet can be common tablet, effervescent tablet, dispersible tablet or other various suitable tablets, can be with suitable coating material coating also coating not; The preferred particulates agent.
The present invention's (prostatitis peace granule) has the chronic prostatitis rat and reduces the blood leukocytes counting, suppresses the pathological change effect of being significantly improved that tissue weight increases, prostata tissue is taken place.The prostatic hyperplasia that the urogenital sinus implantation is caused adult mice has certain preventive effect.Have and suppress inflammation and significant analgesia role in early stage, late period.2,4 one dinitrophenols are caused rat fever significant protective effect is arranged.Certain clearing away heat and promoting diuresis effect is arranged, and antibacterial confirmation can alleviate the zoogenetic infection symptom in the body, prolongs the death time, and the surviving animals number presents dose dependent.It is to staphylococcus aureus, group B streptococcus and colibacillary EDM and 95% fiducial limit thereof.
Following experimental example is used to further specify the present invention.
Experimental example 1 prostatitis peace is to the influence of rat chronic prostatitis model
70 of Wistar rats, male, be divided into 7 groups at random by body weight: high, medium and low dosage group is pacified in normal control group, model control group, QIANLIEKANG matched group, diclofenac matched group, prostatitis.With reference to method anaesthetize, aseptic operation operation, fixing bladder, expose the prostate siphonal lobe, in prostate, inject mixing proinflammatory agent (formaldehyde one Oleum Tiglii of 3.3mol/L 8: 2) 10ul with aseptic micro sample adding appliance, the normal control group is injected physiological saline solution 10ul in prostate, all the other operations are the same.Postoperative 24 hours is all to SMZ-Co gastric infusion 1ml/100 weight portion, continuous 2 times.Postoperative normal control group after 24 hours, model control group irritate stomach for equal-volume water.All the other each medicine groups are all irritated stomach, continuous 10 days by above-mentioned dosage.Fasting was 8 hours in the 11st day, and the socket of the eye vein is got blood 0.5ml, does the numeration of leukocyte inspection.The result organizes t check, dissects rat immediately after getting blood, gets prostate, with 100,000/ scales/electronic balance weighing, calculate dirty/body ratio, the result organizes a t and checks, and sees Table 1.
Table 1 prostatitis peace granule to the influence of rat chronic prostatitis model (X ± s, n=10)
Annotate: with normal control group ratio
*P＜0.05,
*P＜0.01
* *P＜0.001
Compare with model control group
△P＜0.05,
△ △ △P＜0.001
By table 1 result as seen, rat significantly raises through operation modeling bleeding from anus numeration of leukocyte, and prostata tissue obviously increases weight.Give to make behind the prostatitis peace granule operation rat serum numeration of leukocyte that in various degree decline is arranged, than higher dosage tangible statistical significance is arranged with model control group; In, low dosage is to the operation rat serum numeration of leukocyte trend that only has certain effect.High, medium and low dosage increases operation rat prostate tissue weight all utmost point significant inhibitory effect, and prompting prostatitis peace granule has the obvious treatment effect to the rat chronic prostatitis.
2. pairs of mouse retention gential sinuses of experimental example implantation causes the preventive effect of prostatic hyperplasia and gets 60 of Male Kunming strain mice, body weight 24-26 weight portion, 10 every group.Be divided into normal control group, model control group, prostatitis and pacify high, medium and low dosage group and stibestrol group.Giving equal-volume water except that normal control group, model control group irritates the stomach, the all pre-administration of all the other medicine groups 3 days, fasting 8 hours with reference to method anaesthetize, the aseptic operation operation, fixing bladder, expose the prostate siphonal lobe, be implanted into the urogenital sinus tissue 0 of 16 days gestational age Mus with aseptic sharp tweezer to the prostate siphonal lobe.1 weight portion; The normal control group is with aseptic sharp tweezer continued stimulus twice in the prostate siphonal lobe, and all the other operations are the same.Postoperative 24 hours is all to SMZ-Co gastric infusion 1ml/100 weight portion, continuous 2 times.Postoperative normal control group after 24 hours, model control group irritate stomach for equal-volume water.All the other each medicine groups continue to irritate stomach, continuous 27 days.Medication finishes back 24 hours, cut open immediately and get prostate, with 100,000/ scales/electronic balance weighing, calculate dirty/body ratio, the result organizes a t check, sees Table 2.
Table 2 QIANLIE TAI granule to prostatic hyperplasia influence (X ± S, n=10)
By table 2 result as seen, the urogenital sinus implantation can cause the adult mice prostatic hyperplasia, shows that prostata tissue obviously increases weight.Give can make the increase of adult mice prostata tissue weight not remarkable behind the prostatitis peace granule, have respectively extremely significantly and significant differences than higher, middle dosage, the low dosage trend that also has certain effect with model control group: but action intensity is not as stibestrol.Prompting prostatitis peace granule has certain preventive effect to the prostatic hyperplasia that the urogenital sinus implantation causes adult mice.
According to above clinical pharmacology result of study, the present invention has QI invigorating really and holds up unit, clearing away heat-damp and promoting diuresis, the effect of anti inflammatory blood quickening, can play fine therapeutical effect to prostatitis, have good effect, the cycle is short, price is low, do not have any untoward reaction, patient's medication is convenient, economical, can be continuously, long-term prescription and be unlikely to produce toxic and side effects to organ injuries such as liver and kidneys; The chronic disease prostatitis is had good effect, is the prostatitic active drug of a kind of control that the patient takes like a shot.
The specific embodiment
Describe implementation of the present invention in detail below in conjunction with embodiment.
Embodiment 1:
The preparation method of dissolved granule of the present invention:
Take by weighing each raw material; The Radix Astragali 500 grams, the Rhizoma Anemarrhenae 400 grams, Cortex Phellodendri 400 grams, Radix Bupleuri 250 grams, succinum 250 grams, Semen Plantaginis 250 grams, Herba Taraxaci 250 grams, Rhizoma Alismatis 150 grams
Coarser powder is ground in the said medicine pulverizing, except that succinum, other 7 flavor Chinese medicine decocting secondary, 3 hours for the first time, 2 hours for the second time, to filter, filtrate is condensed into thick paste, drying, pulverized 100 mesh sieves, add the succinum mixing, moistening, soften, take out when forming agglomerate, make dissolved granule.
In like manner, press the method for embodiment 1, add suitable additives and can be made into tablet or capsule etc.
Preparation of the present invention is brown granular or grey black tablet or capsule, the tool aromatic odor, and mildly bitter flavor acid, nontoxic, be pure Chinese medicine compound granule or tablet or capsule.
Claims (7)
1. treat prostatitic Chinese medicine composition for one kind, it is characterized in that: it makes active component by the water extract of following raw materials according and pharmaceutically receptible additives are formed, and the weight portion of each raw material is: 166～498 parts of 166～498 portions of Rhizoma Alismatis of 166～498 parts of Herba Taraxacis of 166～498 portions of Semen Plantaginiss of 166～498 parts of succinums of 248～498 parts of Radix Bupleuri of 248～498 portions of Cortex Phellodendris of 331～999 parts of Rhizoma Anemarrhenaes of the Radix Astragali.
2. the prostatitic Chinese medicine composition of a kind of treatment according to claim 1 is characterized in that: described pharmaceutically receptible additives are following more than one: glycerol, gelatin, Polyethylene Glycol, propylene glycol, dextrin, dried starch, ethylparaben, tartaric acid, citric acid, sodium bicarbonate, lecithin and sodium lauryl sulphate.
One kind the treatment prostatitic Chinese medicine composition preparation method, it is characterized in that: it makes active component by the water extract of following raw materials according and pharmaceutically receptible additives are formed, and the weight portion of each raw material is: 166～498 parts of 166～498 portions of Rhizoma Alismatis of 166～498 parts of Herba Taraxacis of 166～498 portions of Semen Plantaginiss of 166～498 parts of succinums of 248～498 parts of Radix Bupleuri of 248～498 portions of Cortex Phellodendris of 331～999 parts of Rhizoma Anemarrhenaes of the Radix Astragali; Comprise the steps:
(a) take by weighing the Radix Astragali, the Rhizoma Anemarrhenae, Cortex Phellodendri, Radix Bupleuri, succinum, Semen Plantaginis, Herba Taraxaci, the former medicine of Rhizoma Alismatis and that coarser powder is ground in its pulverizing is standby by weight;
(b) Radix Astragali, the Rhizoma Anemarrhenae, Cortex Phellodendri, Radix Bupleuri, Semen Plantaginis, Herba Taraxaci, the Rhizoma Alismatis with described weight portion decocts with water twice, add water serves as easy not have powder at every turn, merge decocting liquid twice, filter to get filtrate, it is 1.15～1.35 extractum that concentrated filtrate becomes proportion, dry under 45～55 ℃, get dry extract;
(c) described succinum merges dry extract, is ground into fine powder, is prepared into the active component of medicine;
(d) with gained active component and the abundant mixing of correctives, make pharmaceutically acceptable any dosage form.
4. a kind of preparation method for the treatment of prostatitic Chinese medicine composition according to claim 3 is characterized in that: during with the medicine extracting in water, add 10 times in water for the first time in the step (b), decocted 2 hours, add 8 times in water the second time, decocted 1.5 hours; Spissated extractum proportion is 1.20.
5. the prostatitic Chinese medicine composition of a kind of treatment according to claim 1, it is characterized in that: its dosage form is effervescent granule electuary, capsule or tablet.
6. the prostatitic Chinese medicine composition of a kind of treatment according to claim 5, it is characterized in that: described capsule is the effervescent capsule.
7. the prostatitic Chinese medicine composition of a kind of treatment according to claim 5 is characterized in that: described tablet is effervescent tablet or is dispersible tablet, with suitable coating material coating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510061802 CN1814148B (en) | 2005-12-05 | 2005-12-05 | Chinese medicine composition for treating prostatitis and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510061802 CN1814148B (en) | 2005-12-05 | 2005-12-05 | Chinese medicine composition for treating prostatitis and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1814148A CN1814148A (en) | 2006-08-09 |
| CN1814148B true CN1814148B (en) | 2011-08-24 |
Family
ID=36906580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510061802 Expired - Fee Related CN1814148B (en) | 2005-12-05 | 2005-12-05 | Chinese medicine composition for treating prostatitis and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1814148B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108114200A (en) * | 2018-02-01 | 2018-06-05 | 重庆跃龙生物制药有限公司 | For treating prostatitic Chinese medicine composition and preparation method thereof |
| CN110201053B (en) * | 2019-07-15 | 2021-07-09 | 河南白马健康产业有限公司 | Miao medicine prostate paste and preparation method thereof |
-
2005
- 2005-12-05 CN CN 200510061802 patent/CN1814148B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 张奎军，石志超.慢性前列腺炎中医治疗进展.辽宁中医杂志.2005,32(1),85-86. * |
| 李凯英,莫玉芬,梁小丽.慢性前列腺炎中医研究进展.中医研究.2005,18(2),58-60. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1814148A (en) | 2006-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103099959B (en) | Traditional Chinese medicine preparation for treating ulcerative colitis and preparation method thereof | |
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN102145064A (en) | Traditional Chinese medicine composition for treating senile vaginitis and preparation method thereof | |
| CN101954037B (en) | Chinese medicinal preparation for treating prostatitis | |
| CN102058715B (en) | Chinese medicine preparation for treating chronic prostatitis and preparation method thereof | |
| CN102078569B (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN102988675B (en) | Traditional Chinese medicine combination for treating chronic prostatitis and preparation method thereof | |
| CN102988905B (en) | Traditional Chinese medicine preparation for treating epilepsia and preparation method thereof | |
| CN104815192A (en) | Pharmaceutical composition for treating hypertension and application of pharmaceutical composition | |
| CN102772523B (en) | Bitter glossy ganoderma composition for oncotherapy and preparation method of bitter glossy ganoderma composition | |
| CN101530562A (en) | Pharmaceutical composition for treating female kidney-yin deficiency | |
| CN105213974A (en) | One treats lymphadenomatous Chinese medicine composition and application thereof | |
| CN103041262B (en) | Traditional Chinese medicine enema for curing chronic prostatitis and preparing method thereof | |
| CN1814148B (en) | Chinese medicine composition for treating prostatitis and use thereof | |
| CN104940718A (en) | Pharmaceutical composition for treatment of chronic cholecystitis and preparation method thereof | |
| CN100377736C (en) | Proteinuria treating Chinese medicine and its preparing method and use | |
| KR100770634B1 (en) | Pharmaceutical composition for preventing and treatmenting from disease related to renal failure | |
| CN107412661A (en) | A kind of Chinese medicine composition for treating impotence, premature ejaculation and preparation method thereof | |
| CN100473391C (en) | Novel use of Cynoglossum | |
| CN100348241C (en) | Medicine for treating chronic prostatitis and its preparation method | |
| CN103768478A (en) | Traditional Chinese medicine composition for treating prostatitis and preparation method and application thereof | |
| CN110464755A (en) | A kind of Chinese medicine composition tablet for treating acute pyelonephritis | |
| CN105168729A (en) | Traditional Chinese medicine composition for treating dampness-heat stagnation type dysmenorrhea | |
| CN104666712A (en) | Traditional Chinese medicine composition for treating dysmenorrheal with deficiency of qi and blood and preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NINGBO YUANZHI BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: YANG XIONGZHI Effective date: 20110701 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 315100 ZHEJIANG PHARMACEUTICAL COLLEGE, NO. 888, EAST SECTION OF YINXIAN AVENUE, YINZHOU DISTRICT, NINGBO CITY, ZHEJIANG PROVINCE TO: 315100 ROOM 402, BUILDING 10, LANE 68, TAIYU ROAD, YINZHOU DISTRICT, NINGBO CITY, ZHEJIANG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110701 Address after: 315100, room 10, building 68, Lane 402, Tai Mo Road, Ningbo, Zhejiang, Yinzhou District Applicant after: Ningbo Yuanzhi Biotechnology Co., Ltd. Address before: 315100 Zhejiang city of Ningbo province Yinzhou District County Road No. 888 east section of Zhejiang Pharmaceutical College Applicant before: Yang Xiongzhi |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110824 Termination date: 20131205 |